LOVELAND, Colo., March 1, 2011 /PRNewswire/ -- Heska Corporation (Nasdaq: HSKA; "Heska"), a leading provider of advanced diagnostic and specialty products to veterinarians, today announced the addition of a lactate meter analyzer to its portfolio of in-clinic blood analyzers.
Among other features, the handheld portable analyzer is used to measure lactate, and is ideal for both in-clinic and field use. It provides a lactate assay solution to complement the VitalPath® and DRI-CHEM® Analyzers for complete blood analysis.
"Heska is pleased to announce another product collaboration with Roche," commented Michael McGinley, President and Chief Operating Officer of Heska. "This new lactate meter analyzer will complement Heska's full range of blood analyzers, and is another example of our commitment to innovation within the veterinary industry."
Heska Corporation (Nasdaq: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic and monitoring instruments and supplies as well as single use, point-of-care tests, vaccines and pharmaceuticals. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.
This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties including risks related to Heska's reliance on a third party, Roche Diagnostics, to supply the lactate meter analyzers and affiliated consumables of appropriate quality and quantity; competition; uncertainties regarding Heska's ability to successfully commercialize new products; uncertainties regarding Heska's ability to market, sell and distribute products; uncertainties regarding the performance of products in field use as compared to current expectations; uncertainties regarding the outcome of any collaborations between Heska and any third party, including Roche; risks related to relying on the reputation of Heska, Roche or any other entity, which is subject to interpretation and may change over time; uncertainties related to the future development efforts of any third party; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Annual Report on Form 10-K/A for the year ended December 31, 2009 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2010.
|SOURCE Heska Corporation|
Copyright©2010 PR Newswire.
All rights reserved